FDA’s Revised Policy for Development of COVID-19 Tests

by | May 26, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Quality Systems, Requirements

In an effort to accelerate the production of tests for COVID-19, FDA released a new guidance document that will allow for clinical laboratories and commercial manufacturers to accelerate the development of COVID-19 tests. In this guidance document, FDA outlines its policies for the submission of EUA to the FDA for the newly developed test, as well as for the tests that are developed under the authorities of the State and the State takes responsibility of the testing.1

FDA’s Policy for Tests Developed by Laboratories

This newly released guidance allows CLIA certified laboratories to perform specimen testing after the test has cleared validation while the EUA submission is being prepared and submitted to the FDA. This policy is applicable to laboratories that are certified under CLIA and meet the CLIA regulatory requirements to perform high complexity testing. FDA asks laboratories to notify the agency via email of their newly developed test and begin specimen testing if the test has been validated. Laboratories are required to submit EUAs within 15 days of notifying the FDA of their newly developed tests. Failure to do so will result in removal from FDA’s website listing and additional action from the FDA.1

FDA also recommends for laboratories that while their EUA submission is being processed, the first five positive and negative specimens to undergo confirmatory analysis using an EUA authorized assay.

On March 13, 2020, the President issued a “Memorandum on Expanding State-Approved Diagnostic Tests” which allows for States to authorize laboratories to develop and perform tests for COVID-19. In this guidance document, FDA states that it does not intend to object to the use of such tests for specimen testing where the notification validation is not submitted to FDA and the laboratory does not submit an EUA request to FDA. However, FDA does expect that the State authorities that oversee such laboratories to require the development of test methods to validate such tests.1

FDA’s Policy for Tests Developed by Commercial Manufacturers:

FDA does not intend to object to a commercial manufacturer’s development and distribution of SARS-CoV-2 test kits for specimen testing while their EUA submission is in process or being prepared.  However, FDA does require that the tests be appropriately validated, and the manufacturer provides instructions for use of the test and posts data about the test’s performance characteristics on the manufacturer’s website. The manufacturer must also notify FDA via email on the validation and the intent of distribution of the test and must submit an EUA within 15 days.1

Similar to the Laboratories, FDA recommends that manufacturers conduct confirmatory testing on the first five positive and negative specimens using an EUA authorized assay. 1

Need help in preparing your EUA? Call us today at 248-987-4497 or email us at info@emmainternational.com.

1FDA (May 2020) Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) retrieved on 05/19/2020 from https://www.fda.gov/media/135659/download

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This